In reinstating human ADME to its portfolio, SGS strengths its ability to support drug development programmes with critical early clinical data. FANC approval enables SGS to reintroduce ¹⁴C human ADME ...
Prognostic significance of day+14 plasma cell count after initial induction therapy in Acute Myeloid Leukemia. This is an ASCO Meeting Abstract from the 2015 ASCO Annual Meeting I. This abstract does ...